convalescent plasma treatment - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.73 [0.31, 1.76]< 112%4 studies (4/-)75.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.27 [0.06, 1.25]< 10%1 study (1/-)95.3 %some concernnot evaluable moderateimportant-
clinical improvement 1.11 [0.75, 1.62]> 110%2 studies (2/-)69.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
death or ventilation 0.67 [0.14, 3.26]< 10%1 study (1/-)69.0 %lownot evaluable highimportant-
ventilation 1.12 [0.28, 4.47]< 140%2 studies (2/-)43.9 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 0.96 [0.29, 3.17]< 10%1 study (1/-)52.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.